NasdaqGM:CRSPBiotechs
How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story
CRISPR Therapeutics AG reported fourth-quarter 2025 revenue of US$864,000 and a net loss of US$130.61 million, with full-year 2025 revenue of US$3.51 million and a net loss of US$581.6 million.
Against these weaker financial results, investor attention has shifted to the advancing gene-editing pipeline, including zugo-cel’s FDA Regenerative Medicine Advanced Therapy designation and growing Casgevy commercialization.
We’ll now examine how the FDA’s RMAT designation for zugo-cel shapes CRISPR...